Merck hits a bloop single in an epic PhIII CETP cardio contest. Now what?
Merck $MRK has an interesting dilemma on its hands.
The drug’s enormous Phase III study of its CETP drug anacetrapib came through on the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
